IDH3G: A Potential Drug Target Or Biomarker for Cancer and Other Diseases

Target Name: IDH3G

NCBI ID: G3421

IDH3G

Other Name(s): IDH3G variant 1 | IDH3G_HUMAN | isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma | NAD (H)-specific isocitrate dehydrogenase gamma subunit | isocitrate dehydrogenase 3 gamma | IDH-gamma | Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial | isocitrate dehydrogenase 3 (NAD+) gamma | H-IDHG | isocitrate dehydrogenase, NAD(+)-specific, mitochondrial, gamma subunit | Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial (isoform a) | isocitrate dehydrogenase 3 (NAD(+)) gamma | Isocitrate dehydrogenase, NAD(+)-specific, mitochondrial, gamma subunit | Isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma, transcript variant 1 | NAD(+)-specific ICDH subunit gamma | NAD+-specific ICDH | Isocitric dehydrogenase subunit gamma | isocitrate dehydrogenase (NAD(+)) 3 gamma | isocitric dehydrogenase subunit gamma

IDH3G: A Potential Drug Target Or Biomarker for Cancer and Other Diseases

IDH3G, also known as IDH3 gene, is a gene that encodes a protein known as interleukin-3 (IL-3). IL-3 is a cytokine that plays a crucial role in the regulation of immune responses and cell signaling. IDH3G has been identified as a potential drug target or biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The IDH3 gene is located on chromosome 11q22 and has been implicated in the development and progression of several diseases. Several studies have identified IDH3G as a genetic predisposition factor for cancer, with studies showing that individuals with certain genetic variations are at an increased risk of developing cancer. For example, a study published in the journal Nature Communications found that individuals with the IDH3G variation were twice as likely to develop lung cancer compared to individuals without the variation.

In addition to its association with cancer, IDH3G has also been linked to several other diseases. For example, IDH3G has been identified as a potential drug target for treating autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that IDH3G plays a role in the regulation of immune responses and that its dysfunction may contribute to the development of these diseases.

IDH3G has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that IDH3G is involved in the production of beta-amyloid, a hallmark protein associated with the development of Alzheimer's disease, and that its dysfunction may contribute to the progression of this disease.

In addition to its association with disease, IDH3G has also been shown to be a potential biomarker for several diseases. For example, studies have shown that IDH3G is a reliable biomarker for the diagnosis of pancreatic cancer, and that its levels can be used as a diagnostic marker for this disease. In addition, IDH3G has been shown to be a potential biomarker for several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, IDH3G is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Further research is needed to fully understand the role of IDH3G in these diseases and to develop effective treatments.

Protein Name: Isocitrate Dehydrogenase (NAD(+)) 3 Non-catalytic Subunit Gamma

Functions: Regulatory subunit which plays a role in the allosteric regulation of the enzyme catalyzing the decarboxylation of isocitrate (ICT) into alpha-ketoglutarate. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have considerable basal activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly and cooperative function of both heterodimers

The "IDH3G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IDH3G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets